Fintel reports that on April 8, 2025, William Blair initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform recommendation. Analyst Price Forecast Suggests 195.25% Upside As of ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ...

Oculis has significant longer-term potential. However, it remains a high-risk investment given its clinical stage status, and ...

Potent corticosteroids, such as prednisolone, dexamethasone, and betamethasone, increase intraocular pressure more frequently than weaker corticosteroids.

The pupillary dilation caused by phenylephrine and tropicamide can be reversed with dapiprazole hydrocloride (Rev-Eyes™, Storz Ophthalmic ... such as prednisolone, dexamethasone, and ...

Note, both ILUVIEN and YUTIQ are substantially similar ophthalmic intravitreal implants ... intravitreal corticosteroid employ plants such as dexamethasone, and ocular corticosteroid injections ...

CMS’s merit based incentive payment system (MIPS) has evolved, requiring ophthalmology practices to keep pace to avoid penalties.

Let’s look specifically at dexamethasone, a common corticosteroid in emergency medicine, and use current research to describe what the drug does and look at select situations in prehospital care ...

Accelerated changes in the spherical equivalent refraction (SER) and axial length were seen but no changes in the lens power and thickness were seen in pediatric patients.